Article Text

Download PDFPDF
Primary percutaneous coronary intervention versus thrombolytic treatment: long term follow up according to infarct location
  1. J P S Henriques,
  2. F Zijlstra,
  3. A W J van ’t Hof,
  4. M-J de Boer,
  5. J-H E Dambrink,
  6. A T M Gosselink,
  7. J C A Hoorntje,
  8. J P Ottervanger,
  9. H Suryapranata
  1. Department of Cardiology, Isala Klinieken, locatie Weezenlanden, Zwolle, the Netherlands
  1. Correspondence to:
    Dr Arnoud W J van ’t Hof
    Isala Klinieken, locatie Weezenlanden, Department of Cardiology, Groot Wezenland 20, 8011 JW Zwolle, Netherlands; v.r.c.derks{at}


Objectives: To study the clinical significance of infarct location during long term follow up in a trial comparing thrombolysis with primary angioplasty.

Design: Retrospective longitudinal cohort analysis of prospectively entered data.

Setting: Patients with acute ST elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).

Patients: In the Zwolle trial 395 patients with acute STEMI were randomly assigned to intravenous streptokinase or PCI.

Main outcome measures: Survival according to infarct location and treatment after 8 (2) years of follow up.

Results: 105 patients died: 63 patients in the streptokinase group and 42 patients in the primary PCI group (relative risk (RR) 1.6, 95% confidence interval (CI) 1.0 to 2.6; p  =  0.03). In patients with non-anterior STEMI there was no difference in mortality between streptokinase and PCI treated patients (RR 1.1, 95% CI 0.6 to 2.1; p  =  0.68) but the streptokinase group had significantly more major adverse cardiac events (MACE) than the PCI group (RR 2.1, 95% CI 1.2 to 3.6). The number needed to treat to prevent one MACE was four. In patients with anterior STEMI, mortality was higher in the streptokinase group than in the PCI group (RR 2.7, 95% CI 1.4 to 5.5; p  =  0.004). The number needed to treat to prevent one death was five. Kaplan-Meier analysis confirmed the benefits of primary angioplasty in the first year and showed additional benefit of PCI compared with streptokinase between 1–8 years after the acute event.

Conclusions: Patients with anterior STEMI have better long term survival when treated with PCI than with streptokinase. In patients alive one year after the acute event, PCI confers a significant additional survival benefit, probably due to better preserved residual left ventricular function.

  • CI, confidence interval
  • LVEF, left ventricular ejection fraction
  • MACE, major adverse cardiac events
  • PCI, percutaneous coronary intervention
  • RR, relative risk
  • STEMI, ST elevation myocardial infarction
  • acute myocardial infarction
  • angioplasty
  • streptokinase
  • outcome

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Published Online First 14 April 2005

  • No conflicts of interest